– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023...
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...
The first half of 2022 was marked by concerns over inflation, rising interest rates and recession, with the S&P 500 registering its worst half year since 1970. However, not everyone is seeing dark times...
OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences...
– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest...
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1...
– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership...
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak...
Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing....